Birmingham Biotech and the University of Birmingham sign licensing agreement for anti-viral nasal spray against COVID-19
Birmingham, UK, 9th November 2021 / Sciad Newswire / Birmingham Biotech Ltd, an innovator in diagnostic tests, protective nasal sprays and mobile medical facilities, and the University of Birmingham have signed a licensing agreement to commercialise a novel anti-viral nasal spray that protects against COVID-19.
COVID-19 is both contracted and transmitted by inhalation of droplets or aerosols containing the SARS-CoV-2 virus, and the nose is the major viral entry point into the body, making it an ideal target for approaches designed to reduce person-to-person transmission.
For the all the information please click here.